Th e an tip r oliferative p oten cy of th e s e p r os taglan din s is dem o ns trate d in vitro . We con clude th at de te r m in ation o f PGD 2 p ro duction by m as t ce lls m ust take in to con s ider ation rap id con ve rs ion to active der ivatives , w h ic h m ay play a s ign ifican t r ole in gr ow th r egulation .
Introduction
Prostaglandin (PG) D 2 and its metabolites PGJ 2 and D 12 -PGJ 2 are potent antiproliferative eicosanoids. 1 The concentrations of PGD 2 , PGJ 2 and D 12 -PGJ 2 required for regulation of cell proliferation in vitro are in the micromolar range. 1 The high molar activity suggests that these lipid mediators may play a role in the regulation of cell proliferation in vivo and that, on the other hand, this principle may be used in anti-tumour therapy. In fact, the related chemically stabilized prostanoid D 7 -PGA 1 has been proposed for clinical studies.
2 PGD 2 may also represent a component in natural anti-neoplastic defence. Mast cells are regarded as major sources of endogenous PGD 2 production. Murine bone marrow -derived mast cells (BMMC) have been reported to produce 15-120 pmol PGD 2 per million cells during 10-30 min of incubation follow ing different kinds of stimulation. 3, 4 However, these apparently low production rates of PGD 2 are unlikely to exert major biological effects in vivo.
We hypothesized that the reported PGD 2 production rates underestimate biosynthesis of this mediator, because PGD 2 can be converted to other active metabolites including antiproliferative PGJ 2 and D 12 -PGJ 2 . These cyclopentenone prostanoids have been shown to occur in aqueous media, blood plasma and urine. 1 In the present study PGD 2 and its metabolites were detected and quantified in supernatants from murine mast cells by combined use of high performance liquid chromatography (HPLC) and radioimmunoassay (RIA) analysis. The antiproliferative potencies of PGD 2 and its derivatives PGJ 2 and D 12 -PGJ 2 were evaluated testing the effect of these PGs on [ 3 H]-thymidine incorporation into human myelocytic (HL-60), monocytoid (THP-1, U937) and lymphoid (Burkitt, Raji) cell lines and on MTT-conversion by murine bone marrow -derived mast cells (BMMC) and IL-3-dependent and autonomous mast cell lines. H]-T) (37 MBq/ml) were from Amersham-Buchler, Braunschweig, Germany. Calcium-ionophore A23187, indomethacin, 4-hydroxy-2,2,6,6,-tetrametylpiperidine-l-oxyl (HTMP) and gelatine from porcine skin (300 bloom) were from Sigma, St Louis, MO, USA. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium-bromid (MTT) was from Serva, Heidelberg, Germany. Fetal calf serum (FCS) and RPMI 1640 were from Biochrom, Berlin, Germany. The other chemicals used were purchased from Merck, Darmstadt, Germany and were at least of analytical grade.
Materials and Methods

Chemicals
Cells and cell lines
Primary polyclonal BMMC were generated in cultures of murine (BALB/c) bone marrow cells supplemented with pokeweed mitogen-activated spleen cell-conditioned medium (SCM) as previously described. 5 Briefly, murine bone marrow cells (1 3 10 5 /ml) were grown in RPMI-1640 medium supplemented with 20% FCS, 20% SCM, 2 mM L-glutamine, 100 U/ml penicillin-streptomycin and 10 -4 M a -thioglycerol. When propagating non-adherent bone marrow cells in this culture medium with weekly refeeding, homogenous populations of mast cells could be obtained within a period of 3 to 8 weeks. Mast cells used for analysis of eicosanoid production were 21-55 days ex vivo (33 ± 10 days; mean ± standard deviation (SD)). IL-3-dependent long-term cultured mast cell lines were derived from BMMC. 5 A grow th factor independent malignant autonomous mast cell line was derived from an IL-3-dependent long term cultured mast cell line. 6 A human myeloid leukaemic cell line (HL-60) 7 was cultured in RPMI 1640 containing 15% FCS and 100 U/ml penicillin-streptomycin. Human monocytic (THP-1) 8 and histiocytic (U937) 9 cell lines were cultured in RPMI 1640 with 10% FCS and 100 U/ml penicillin-streptomycin. Human Burkitt 10 and Raji 11 lymphoma cell lines were cultured in RPMI 1640 containing 10% FCS and 100 U/ml penicillin-streptomycin. HL-60-, THP-1-, U937-, Burkitt and Raji lymphoma cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were cultured at 37°C under humidified atmosphere with 5% (mast cells) or 10% CO 2 .
Determination of prostaglandin and leukotriene production
For analysis of radioactive AA-metabolites 5 3 10 7 of BMMC were prelabelled with [
14 C]-AA (18.5 kBq/ml) for 48 h. Cells were washed tw ice and resuspended in PBS (10 7 cells/ml) containing gelatine (0.5 mg/ml) or in culture medium (RPMI 1640 with 20% FCS). After a 5-min period of preincubation, cells were incubated with or w ithout calcium ionophore A23187 (0.2 m M) at 37°C. Incubation was stopped by centrifugation (10 min at 4°C and 600 3 g ). For deproteinization supernatant and pellet were seperated and added to 8 volumes of 90% aqueous methanol containing 0.5 mM EDTA and 1 mM HTMP, pH 7.4. HTMP was used for stabilization of lipid mediators. The suspensions were stored at -40°C for at least 12 h and then centrifuged (20 min at -10°C and 9000 3 g ). Supernatants were evaporated to dryness in a centrifuge under low pressure (Speed Vac, Savant, Farmingdale, NY, USA) and redissolved in 30% aqueous methanol containing trace amounts of unlabelled PGD 2 , PGJ 2 and Analysis of prostaglandin and leukotriene production by unlabelled mast cells was performed by sequential use of HPLC and RIA. BMMC were washed tw ice and resuspended in PBS (0.5 mg/ml gelatine) at a concentration of 10 6 cells/ml. Incubation and deproteinization were performed as described above. Samples were redissolved in 30% aqueous methanol containing trace amounts of [ 3 H]-labelled PGD 2 or LTC 4 , LTD 4 and LTE 4 standards.
The mobile phase of HPLC for routine prostaglandin analysis consisted of methanol, water, acetic acid (65:35:0.1 by volume), pH 4.0 adjusted w ith ammonium hydroxide (flow rate: 0.4 ml/min). For confirmation of the identity of endogenously produced PGD 2 metabolites, additional solvent systems were used: acetonitrile, water, acetic acid (40:60:0.1 by volume), flow rate: 0.4 ml/min and acetonitrile, water and acetic acid (50:50:0.1 by volume), flow rate: 0.5 ml/min. The mobile phase for routine leukotriene analysis consisted of methanol, water, acetic acid (65:35:0.1 by volume), pH 5.6 adjusted w ith ammonium hydroxide (flow rate: 1.0 ml/min). HPLCfractions were collected in 0.5-min intervals. An aliquot of these fractions was counted for tritium radioactivity to determine retention time of 
(2) (10) 3 H]-T in microtitre plates (37 kBq/well) cells were collected on glassfibre filters by a cell harvester (CanberraPackard, Dreieich, Germany) and radioactivity associated w ith the washed and dried filters was quantified with a Matrix 96 counter (Canberra-Packard, Dreieich, Germany) as b -counts. Alternatively, a colorimetric proliferation assay, the MTT-test, was used as described. 5 Briefly, cultured cells in microtitre plates were incubated for 4 h with MTT. Incubation was stopped with acidified isopropanol. Optical density (OD) was detected in a ELISA-reader (SLT, Salzburg, Austria) at a test wave length of 550 nm and a reference wave length of 690 nm. Results are shown as OD 550-690 values. (Fig. 1) . The total concentration of these mediators amounted to 153.6 ± 78.4 pmol/10 6 cells (n = 4) (Fig.  2) . The relative quantities of PGD 2 , PGJ 2 and D 12 -PGJ 2 were 11 ± 8%, 53 ± 18% and 36 ± 17% (n = 4, mean ± SD), respectively ( Figs. 1 and 2) . The A23187-stimulated release of PGD 2 , PGJ 2 plus D 12 -PGJ 2 was 169% ± 14% of the unstimulated samples (n = 3, mean ± SD) (Fig. 2) . 4 . BMMC were suspended in PBS with (+) or without (-) calcium ionophore A23187 (0.2m M) for 30 min at 37°C. Results are given as mean ± SD or range of two to 10 independent experiments (number in parenthesis). (Fig. 3) . Following 30 min of incubation in PBS or culture medium 19% or 33% of [ 3 H]-PGD 2 were metabolized, respectively. The half-life of PGD 2 was more than 10 h in PBS and 3 h in culture medium. Metabolism of extracellular PGD 2 was not altered in the presence of 10 6 BMMC per ml. Gelatine (0.5 mg/ml) had also no effect on PGD 2 metabolism. The procedures of sample preparation had no influence on recovery or metabolism of PGD 2 .
Results
Mast cells release PGD
Im portance o f metabo lite form atio n for antipro liferative activity
BMMC produce large amounts of LTC 4 Following 30 min of incubation, BMMC produced 85.4 ± 74.0 pmol LTC 4 /10 6 cells (n = 10) and 42. 33.8 pmol LTC 4 /10 6 cells (n = 5; mean ± SD) with and without calcium ionophore A23187 (0.2 m M), respectively. LTC 4 was not metabolized to LTD 4 Fig. 4) . The IC 50 values varied between 2.5 and 80 m M in different cell types. PGD 2 , PGJ 2 and D 12 -PGJ 2 were equally effective. At concentrations below 0.5 m M, no significant effect on cell proliferation was observed. Indomethacin (0.1 mM to 10 nM) had no influence on the proliferation of BMMC, TPH-1, U937 or HL-60 cells (Fig. 4) . PGD 2 was rapidly metabolized in culture medium to PGJ 2 D 12 -PGJ 2 and other not identified metabolites or conjugates.
Discussion
Our data demonstrate that murine BMMC release PGD 2 and LTC 4 , potent eicosanoid mediators. PGD 2 undergoes immediate metabolism to PGJ 2 and D 12 -PGJ 2 during production by BMMC (Fig. 1) . This rapid metabolism of PGD 2 is not explained by degradation in extracellular fluid, because the half-life of PGD 2 is more than 10 h in PBS and 3 h in culture medium containing FCS. Mast cells do not contribute to conversion of extracellular PGD 2 .
The total of PGD 2 , PGJ 2 and D 12 -PGJ 2 produced by stimulated mast cells is about eight-fold the amount of PGD 2 alone (Figs 1 and 2) . Separation of PGD 2 -metabolites is required prior to RIA, because considerable differences exist in the immunoreactivity of the various PGD 2 metabolites corresponding to very different cross-reactivity profiles in radio-immunologic analysis. Direct radio-immunologic analysis 3 may thus result in gross underestimation of the PGD 2 production and of the PGD 2 mediated antiproliferative potential of BMMC. Stimulation of BMMC w ith A23187 significantly increased the release of PGD 2 , PGJ 2 and D 12 -PGJ 2 in total. This is largely due to an increased release of the latter tw o metabolites (Fig. 2) .
A (Fig. 3) and the fact that there were no significant differences in the antiproliferative effects of PGD 2 , PGJ 2 and D 12 -PGJ 2 in the proliferation assays using incubation times of 24 h (Table 1, Fig. 4 ) are both in line with the suggestion of Narumiya and Fukushima 1, 15 , that D 12 -PGJ 2 is the active metabolite of PGD 2 and that PGD 2 may ex ert no grow th inhibition by itself.
The mechanism of action of D 12 -PGJ 2 is not fully understood. There are no surface receptors. The lipid mediator is actively transported into cells through a temperature-dependent transporter on plasma membranes. D 12 -PGJ 2 accumulates in the nuclei, where it binds to thiol groups of nuclear proteins. 16 Gluthatione depletion enhances antiproliferative activity of PGJ 2 and D 12 -PGJ 2 . 14 Recently it has been shown that intracellular glutathione modulates induction of apoptosis by D 12 -PGJ 2 .
17 PGD 2 and its metabolites ex erted a more distinct antiproliferative effect in lymphocytic, myelocytic and mast cells than in monocytic or histiocytic cells. Primary murine BMMC were more resistant to growth inhibition by PGD 2 , PGJ 2 or D 12 -PGJ 2 than IL-3-dependent and autonomous mast cell lines (Table  1) . Indomethacin had no effect on proliferation of BMMC, U937 or HL-60 cells in the proliferation assays used.
We conclude that measurement of PGD 2 disregarding its conversion to metabolites may grossly underestimate PGD 2 production and effects related to these mediators. Our results suggest that the total of PGD 2 , PGJ 2 and D 12 -PGJ 2 produced by stimulated mast cells may be expected to exert significant antiproliferative activity. Production of antiproliferative PGD 2 metabolites by BMMC in vitro raises the possibility that mast cells exert an anti-proliferative and anti-neoplastic activity by the release of anti-proliferative PGD 2 metabolites in vivo .
